NSG 552
PSYCHOPHARMACOLOGY EXAM
3 ACTUAL 2026/2027 - COMPLETE
LATEST MOCK PRACTICE SET
190 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 552 PSYCHOPHARMACOLOGY EXAM 3 ACTUAL 2026/2027 - COMPLETE EXAM-STYLE QUESTIONS |
100% VERIFIED - PASS GUARANTEED - A+ GRADED. It contains 190 carefully selected questions that reflect
the most current exam content and testing strategies. Each question is accompanied by a correct answer and a
detailed rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 190 Questions
Foundations - Application - NSG 552 Psychopharmacology 3 Actual 2026/2027 Complete -style 100 PASS
Guaranteed A Psychopharmacology Graduate Nurse Practitioner / Clinical Doctorate
All answers with rationales
,Table of Contents
Section A - Disorder Section B - Bipolar
Questions 1 to 48 Questions 49 to 96
Section C - Depression Section D - Appropriate
Questions 97 to 144 Questions 145 to 190
,Section A - Disorder
Q1.
A patient on long-term fluoxetine develops serotonin syndrome after adding linezolid.
Which receptor subtype is primarily responsible for the life-threatening features of
hyperthermia and muscle rigidity?
A. 5-HT2A B. 5-HT1A
C. 5-HT3 D. 5-HT2C
Correct: A - 5-HT2A
Rationale:5-HT2A receptor overstimulation is implicated in serotonin syndrome's
hyperthermia, clonus, and hyperreflexia. 5-HT1A contributes to anxiety and autonomic effects
but not the severe motor symptoms. 5-HT3 relates to GI effects; 5-HT2C affects appetite.
Q2.
Which pharmacogenetic polymorphism is most consistently associated with poor
response to CYP2D6-metabolized antidepressants like paroxetine?
A. CYP2C19 poor metabolizer B. CYP2D6 ultra-rapid metabolizer
C. CYP3A4 inducer phenotype D. ABCB1 C3435T TT genotype
Correct: B - CYP2D6 ultra-rapid metabolizer
Rationale:Ultra-rapid CYP2D6 metabolizers rapidly clear paroxetine, reducing efficacy. Poor
metabolizers have higher levels and increased side effects. CYP2C19 affects drugs like
citalopram; ABCB1 influences blood-brain barrier transport, but CYP2D6 status is primary for
paroxetine.
Q3.
A patient stabilized on clozapine develops new-onset tachycardia and hypotension. Labs
show elevated troponin and CRP. Which intervention is most appropriate?
A. Continue clozapine and add metoprolol B. Reduce clozapine dose and recheck labs
in 24 hours
C. Discontinue clozapine immediately and D. Switch to olanzapine to maintain
obtain echocardiogram antipsychotic efficacy
Correct: C - Discontinue clozapine immediately and obtain echocardiogram
Page 3
, Section A - Disorder
Rationale: This presentation suggests clozapine-induced myocarditis, which is life-threatening
and requires immediate discontinuation and cardiac evaluation. Continuing or reducing dose
is unsafe. Switching to olanzapine may be considered later but not before ruling out
myocarditis.
Q4.
A patient on valproate for bipolar disorder has a new seizure and labs show ammonia 80
µmol/L (normal 11-35). Which co-administered medication most likely contributed to this
hyperammonemia?
A. Lamotrigine B. Risperidone
C. Topiramate D. Lithium
Correct: C - Topiramate
Rationale:Topiramate increases the risk of valproate-induced hyperammonemic
encephalopathy, even with therapeutic valproate levels. Lamotrigine, risperidone, and lithium
do not have this interaction. Ammonia levels should be monitored when combining these
agents.
Q5.
For a patient with treatment-resistant depression who has failed two SSRIs and one SNRI,
which augmentation strategy has the strongest evidence for rapid efficacy in reducing
suicidal ideation?
A. Aripiprazole augmentation B. Lithium augmentation
C. Intravenous ketamine D. Thyroid hormone (T3) augmentation
Correct: C - Intravenous ketamine
Rationale:Intravenous ketamine has demonstrated rapid (within hours) reduction in suicidal
ideation, even before antidepressant effect. Lithium reduces suicide risk long-term but not
acutely. Aripiprazole and T3 take weeks and have less evidence for acute suicidality.
Q6.
A patient with bipolar depression is started on lurasidone. Which pharmacokinetic
property requires administration with food to ensure adequate absorption?
A. High first-pass metabolism B. Food increases AUC by approximately
2-fold
C. P-glycoprotein substrate D. pH-dependent solubility
Correct: B - Food increases AUC by approximately 2-fold
Page 4
PSYCHOPHARMACOLOGY EXAM
3 ACTUAL 2026/2027 - COMPLETE
LATEST MOCK PRACTICE SET
190 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NSG 552 PSYCHOPHARMACOLOGY EXAM 3 ACTUAL 2026/2027 - COMPLETE EXAM-STYLE QUESTIONS |
100% VERIFIED - PASS GUARANTEED - A+ GRADED. It contains 190 carefully selected questions that reflect
the most current exam content and testing strategies. Each question is accompanied by a correct answer and a
detailed rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 190 Questions
Foundations - Application - NSG 552 Psychopharmacology 3 Actual 2026/2027 Complete -style 100 PASS
Guaranteed A Psychopharmacology Graduate Nurse Practitioner / Clinical Doctorate
All answers with rationales
,Table of Contents
Section A - Disorder Section B - Bipolar
Questions 1 to 48 Questions 49 to 96
Section C - Depression Section D - Appropriate
Questions 97 to 144 Questions 145 to 190
,Section A - Disorder
Q1.
A patient on long-term fluoxetine develops serotonin syndrome after adding linezolid.
Which receptor subtype is primarily responsible for the life-threatening features of
hyperthermia and muscle rigidity?
A. 5-HT2A B. 5-HT1A
C. 5-HT3 D. 5-HT2C
Correct: A - 5-HT2A
Rationale:5-HT2A receptor overstimulation is implicated in serotonin syndrome's
hyperthermia, clonus, and hyperreflexia. 5-HT1A contributes to anxiety and autonomic effects
but not the severe motor symptoms. 5-HT3 relates to GI effects; 5-HT2C affects appetite.
Q2.
Which pharmacogenetic polymorphism is most consistently associated with poor
response to CYP2D6-metabolized antidepressants like paroxetine?
A. CYP2C19 poor metabolizer B. CYP2D6 ultra-rapid metabolizer
C. CYP3A4 inducer phenotype D. ABCB1 C3435T TT genotype
Correct: B - CYP2D6 ultra-rapid metabolizer
Rationale:Ultra-rapid CYP2D6 metabolizers rapidly clear paroxetine, reducing efficacy. Poor
metabolizers have higher levels and increased side effects. CYP2C19 affects drugs like
citalopram; ABCB1 influences blood-brain barrier transport, but CYP2D6 status is primary for
paroxetine.
Q3.
A patient stabilized on clozapine develops new-onset tachycardia and hypotension. Labs
show elevated troponin and CRP. Which intervention is most appropriate?
A. Continue clozapine and add metoprolol B. Reduce clozapine dose and recheck labs
in 24 hours
C. Discontinue clozapine immediately and D. Switch to olanzapine to maintain
obtain echocardiogram antipsychotic efficacy
Correct: C - Discontinue clozapine immediately and obtain echocardiogram
Page 3
, Section A - Disorder
Rationale: This presentation suggests clozapine-induced myocarditis, which is life-threatening
and requires immediate discontinuation and cardiac evaluation. Continuing or reducing dose
is unsafe. Switching to olanzapine may be considered later but not before ruling out
myocarditis.
Q4.
A patient on valproate for bipolar disorder has a new seizure and labs show ammonia 80
µmol/L (normal 11-35). Which co-administered medication most likely contributed to this
hyperammonemia?
A. Lamotrigine B. Risperidone
C. Topiramate D. Lithium
Correct: C - Topiramate
Rationale:Topiramate increases the risk of valproate-induced hyperammonemic
encephalopathy, even with therapeutic valproate levels. Lamotrigine, risperidone, and lithium
do not have this interaction. Ammonia levels should be monitored when combining these
agents.
Q5.
For a patient with treatment-resistant depression who has failed two SSRIs and one SNRI,
which augmentation strategy has the strongest evidence for rapid efficacy in reducing
suicidal ideation?
A. Aripiprazole augmentation B. Lithium augmentation
C. Intravenous ketamine D. Thyroid hormone (T3) augmentation
Correct: C - Intravenous ketamine
Rationale:Intravenous ketamine has demonstrated rapid (within hours) reduction in suicidal
ideation, even before antidepressant effect. Lithium reduces suicide risk long-term but not
acutely. Aripiprazole and T3 take weeks and have less evidence for acute suicidality.
Q6.
A patient with bipolar depression is started on lurasidone. Which pharmacokinetic
property requires administration with food to ensure adequate absorption?
A. High first-pass metabolism B. Food increases AUC by approximately
2-fold
C. P-glycoprotein substrate D. pH-dependent solubility
Correct: B - Food increases AUC by approximately 2-fold
Page 4
